Hyaluronic acid targeted metal organic framework based on iron (III) for delivery of platinum curcumin cytotoxic agent to triple negative breast cancer cell line

Abstract

Platinum‐based drugs are an essential class of chemotherapy drugs in breast cancer. However, suffer from side effects and drug resistance; structural changes and applying drug carriers can lead to new drug candidates in this class. The metal‐organic frameworks (MOFs) as porous carriers have recently attracted much attention in drug delivery. In this study, for the first time, hyaluronic acid (HA)‐targeted MOF (NH2‐MIL‐101 (Fe)) nanoparticles (Pt‐CUR@MIL@HA NPs) were evaluated in delivery of platinum‐curcumin (Pt‐CUR) prodrug to the MDA‐MB‐231 triple‐negative breast cancer cell line; in this regard, the cytotoxicity, ROS production, and cellular uptake of designed NPs have been studied. Different analysis methods confirmed chemical structures, the prepared NPs had a uniform morphology, and the hydrodynamic size of the optimized non‐targeted loaded particles increased to about 252 nm with a zeta potential of +26.9 mV, after targeting with HA, the size increased to 310 nm, and the zeta potential changed to −28 mV. Based on TGA and atomic absorption (ICP‐MS) results, the drug loading percent was determined to be about 30%–35%. Drug release from the HA targeted Pt‐CUR@MIL@HA system in the neutral condition was slow and sustained, and after 36 h, a maximum of 60% of the drug was released, but in acidic conditions, the release was increased, and by 18 h, the release was about 80%. The cytotoxicity of MOF NPs containing Pt‐CUR was more significant than that of the free drug, and HA targeted has resulted in more cellular uptake than the non‐targeted NPs. In conclusion, these new MOF‐ based HA‐coated NPs of PT‐CUR can be introduced to pre‐clinical researches after completing in vitro and in vivo studies.

Nanoscale metallic‐organic frameworks as an advanced tool for medical applications: Challenges and recent progress

“…Moradi et al [ 37 ] used hyaluronic acid (HA)‐modified NH 2 ‐MIL‐101 (Fe) for the targeted delivery of platinum and curcumin (CUR). HA has a high affinity to CD44 receptors; hence, HA‐based nanoparticles are a good strategy for anticancer therapeutic agent delivery into CD44‐overexpressing tumor cells.…”

“…Thus, one of the main challenges is to reduce these side effects through targeted delivery of therapeutic agents to cancer cells via three main approaches: (1) Passive targeting, which mainly relies on the enhanced permeability and retention (EPR) phenomenon, (2) active targeting, which uses antibodymodified vectors with high affinity toward cancerous cells or magnetic targeting, and (3) triggered release, under certain external stimuli such as heat, light, or ultrasounds. [36] Moradi et al [37] used hyaluronic acid (HA)-modified NH 2 -MIL-101 (Fe) for the targeted delivery of platinum and curcumin (CUR). HA has a high affinity to CD44 receptors; hence, HA-based nanoparticles are a good strategy for anticancer therapeutic agent delivery into CD44-overexpressing tumor cells.…”